Compare VolitionRX Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 36 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.30
68.61%
-1.03
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Sep 2025)
Net Profit:
-5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-92.08%
0%
-92.08%
6 Months
-93.72%
0%
-93.72%
1 Year
-95.31%
0%
-95.31%
2 Years
-88.8%
0%
-88.8%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
VolitionRX Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.13%
EBIT Growth (5y)
-5.24%
EBIT to Interest (avg)
-28.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
-0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
26.80%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.06
EV to EBIT
-2.53
EV to EBITDA
-2.67
EV to Capital Employed
-2.58
EV to Sales
46.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 5 Schemes (2.12%)
Foreign Institutions
Held by 8 Foreign Institutions (0.08%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
0.60
0.40
50.00%
Operating Profit (PBDIT) excl Other Income
-4.80
-6.00
20.00%
Interest
0.90
0.40
125.00%
Exceptional Items
0.30
0.40
-25.00%
Consolidate Net Profit
-5.40
-6.30
14.29%
Operating Profit Margin (Excl OI)
-8,132.00%
-15,485.60%
735.36%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 50.00% vs 100.00% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 14.29% vs -14.55% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1.20
0.80
50.00%
Operating Profit (PBDIT) excl Other Income
-25.70
-34.60
25.72%
Interest
0.30
0.20
50.00%
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-27.30
-35.70
23.53%
Operating Profit Margin (Excl OI)
-21,909.00%
-46,417.60%
2,450.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 50.00% vs 166.67% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 23.53% vs -16.67% in Dec 2023
About VolitionRX Ltd. 
VolitionRX Ltd.
Pharmaceuticals & Biotechnology
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.
Company Coordinates 
Company Details
Galleria Oaks B , AUSTIN TX : 78738-6439
Registrar Details






